Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by Citizens Jmp

Blueprint Medicines (NASDAQ:BPMC) was downgraded by investment analysts at Citizens Jmp from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Scotiabank downgraded Blueprint Medicines from a “strong-buy” rating to a “hold” rating and set a $135.00 price objective for the company. in a research report on Monday. Morgan Stanley began coverage on Blueprint Medicines in a research report on Thursday, March 20th. They issued an “equal weight” rating and a $100.00 target price for the company. Jefferies Financial Group began coverage on Blueprint Medicines in a research report on Monday, March 17th. They issued a “buy” rating and a $135.00 target price for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $129.00 target price (down previously from $130.00) on shares of Blueprint Medicines in a research report on Monday. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Blueprint Medicines in a research report on Tuesday. Fourteen research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines has a consensus rating of “Hold” and an average target price of $125.38.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC opened at $127.60 on Tuesday. Blueprint Medicines has a one year low of $73.04 and a one year high of $128.15. The stock has a fifty day moving average of $93.17 and a 200-day moving average of $95.16. The company has a market capitalization of $8.24 billion, a PE ratio of -118.15 and a beta of 0.83. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. During the same quarter last year, the company posted $1.40 EPS. Blueprint Medicines’s revenue was up 55.5% on a year-over-year basis. As a group, equities analysts anticipate that Blueprint Medicines will post -1.28 EPS for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 2,752 shares of the firm’s stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $103.13, for a total transaction of $283,813.76. Following the transaction, the insider now directly owns 16,944 shares in the company, valued at $1,747,434.72. This trade represents a 13.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $101.75, for a total value of $231,379.50. Following the transaction, the chief operating officer now owns 66,992 shares in the company, valued at approximately $6,816,436. This trade represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,574 shares of company stock worth $1,465,528 over the last three months. Corporate insiders own 4.21% of the company’s stock.

Hedge Funds Weigh In On Blueprint Medicines

A number of institutional investors have recently made changes to their positions in BPMC. KBC Group NV increased its stake in shares of Blueprint Medicines by 63.9% in the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 1,023 shares during the period. Jennison Associates LLC bought a new position in shares of Blueprint Medicines in the fourth quarter worth about $31,417,000. Stephens Inc. AR bought a new position in shares of Blueprint Medicines in the fourth quarter worth about $321,000. Values First Advisors Inc. increased its stake in shares of Blueprint Medicines by 277.9% in the fourth quarter. Values First Advisors Inc. now owns 4,970 shares of the biotechnology company’s stock worth $433,000 after purchasing an additional 3,655 shares during the period. Finally, Van ECK Associates Corp increased its stake in shares of Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 363 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.